*Based on commercial patients, early access patients, and clinical trial participants through September 2021.
SPINRAZA is directly delivered to
the central nervous system (CNS)
motor neuron loss begins.
initial loading doses,
given 3 times a year.
There’s someone from almost every
age group who has been treated
†Includes clinical trial patients.
‡Pivotal clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto
Rico) through December 2020.
The most common side effects of
SPINRAZA include lower respiratory
infection, fever, constipation, headache,
vomiting, back pain, and post-lumbar
puncture syndrome. These are not all of
the possible side effects of SPINRAZA.